Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

Hikma Pharmaceuticals upgraded to ‘BBB’ by Fitch with stable outlook

Hikma Pharmaceuticals has received a Fitch upgrade to 'BBB' for its long-term issuer default rating, highlighting its financial strength and strategic position...

Nuformix granted EU Orphan Drug Status for IPF treatment NXP002

Nuformix plc secures Orphan Drug Designation for NXP002 in Idiopathic Pulmonary Fibrosis, enhancing treatment options for this rare disease...

AstraZeneca Plc Imfinzi recommended for EU approval in bladder cancer

AstraZeneca's Imfinzi gains EU approval for treating muscle-invasive bladder cancer, offering a promising neoadjuvant and adjuvant therapy based on pivotal trial results...

GSK Plc Nucala approved by FDA for Eosinophilic COPD

GSK's Nucala (mepolizumab) gains FDA approval as a crucial add-on treatment for adults with inadequately controlled COPD and eosinophilic phenotype...

HUTCHMED showcases new oncology data at ASCO 2025

HUTCHMED (China) Limited is set to unveil groundbreaking data on key cancer therapies at the 2025 ASCO Annual Meeting, highlighting promising advancements in NSCLC and solid tumors...

Compassionate gynaecology care with NHS efficiency

Experience advanced gynaecological care at One Health, where NHS expertise meets modern techniques for swift and effective treatment of women’s health conditions...

Precision-driven recruitment that accelerates clinical trial success

Discover how hVIVO's recruitment division sets the gold standard in clinical trials, delivering efficient, tailored participant sourcing for diverse studies...

Oxford Nanopore unveils tech and pipeline updates at London Calling 2025

Oxford Nanopore Technologies recently unveiled innovative updates at its London Calling conference, showcasing advancements in nanopore sequencing technology and its applications...

Nuformix raises £210,000 to advance NXP002 and US Orphan Drug Application

Nuformix plc (LON:NFX) aims to raise £210,000 through a conditional placing to advance its NXP002 inhalation treatment for IPF and PPF...

Poolbeg Pharma raises £4.7m through Placing and Subscription

Poolbeg Pharma has successfully raised £4.715 million to fund innovative clinical trials, including POLB 001 and an oral GLP-1 programme, addressing critical medical needs...

AstraZeneca Plc acquires EsoBiotec in $1bn cell therapy deal

AstraZeneca has successfully acquired EsoBiotec, enhancing its cancer therapy capabilities with innovative in vivo cell therapies that promise faster treatment access...

Poolbeg Pharma launches £4.1m fundraising

Poolbeg Pharma plc (LON:POLB) announces a conditional fundraising aimed at raising £4.1 million to drive innovative pharmaceutical developments and address unmet medical needs...

Cizzle Biotechnology raises £150k to support cancer test rollout

Cizzle Biotechnology Holdings Plc has raised £150,000 to advance its CIZ1B early cancer test, enhancing access to innovative diagnostics in the UK and Europe...

Poolbeg Pharma advances in POLB 001 and GLP-1 trials

Poolbeg Pharma Plc has released its audited results for 2024, highlighting significant advancements in cancer immunotherapy, including the promising POLB 001 therapy...

Poolbeg Pharma targets severe flu and cytokine storms

Poolbeg Pharma's POLB 001 is an innovative, orally-administered treatment aiming to combat severe influenza and cytokine release syndrome, revolutionising immunotherapy...

GSK Plc receives Japan approval for Blenrep combinations in multiple myeloma

GSK's Blenrep combinations gain approval in Japan for relapsed multiple myeloma, offering promising treatment options backed by successful clinical trial results...

Nuformix to present NXP002 data at ATS 2025

Nuformix plc will showcase groundbreaking results on NXP002 at the American Thoracic Society Congress in San Francisco, addressing fibrosis and oncology challenges...

One Health Group unlocks new potential in spinal treatment

Experience relief from back pain with One Health Group, a leader in spinal care. Their expert team offers personalised, advanced treatments for improved mobility and quality of life...

Aptamer secures repeat contracts and new licensing deals

Aptamer Group plc announces promising new data on its Optimer therapeutic delivery platform for liver fibrosis, showcasing broad therapeutic potential across various diseases...
Search

Funds

Health

Hikma Pharmaceuticals upgraded to ‘BBB’ by Fitch with stable outlook

Hikma Pharmaceuticals has received a Fitch upgrade to 'BBB' for its long-term issuer default rating, highlighting its financial strength and strategic position...

Nuformix granted EU Orphan Drug Status for IPF treatment NXP002

Nuformix plc secures Orphan Drug Designation for NXP002 in Idiopathic Pulmonary Fibrosis, enhancing treatment options for this rare disease...

AstraZeneca Plc Imfinzi recommended for EU approval in bladder cancer

AstraZeneca's Imfinzi gains EU approval for treating muscle-invasive bladder cancer, offering a promising neoadjuvant and adjuvant therapy based on pivotal trial results...

GSK Plc Nucala approved by FDA for Eosinophilic COPD

GSK's Nucala (mepolizumab) gains FDA approval as a crucial add-on treatment for adults with inadequately controlled COPD and eosinophilic phenotype...

HUTCHMED showcases new oncology data at ASCO 2025

HUTCHMED (China) Limited is set to unveil groundbreaking data on key cancer therapies at the 2025 ASCO Annual Meeting, highlighting promising advancements in NSCLC and solid tumors...

Compassionate gynaecology care with NHS efficiency

Experience advanced gynaecological care at One Health, where NHS expertise meets modern techniques for swift and effective treatment of women’s health conditions...

Precision-driven recruitment that accelerates clinical trial success

Discover how hVIVO's recruitment division sets the gold standard in clinical trials, delivering efficient, tailored participant sourcing for diverse studies...

Oxford Nanopore unveils tech and pipeline updates at London Calling 2025

Oxford Nanopore Technologies recently unveiled innovative updates at its London Calling conference, showcasing advancements in nanopore sequencing technology and its applications...

Nuformix raises £210,000 to advance NXP002 and US Orphan Drug Application

Nuformix plc (LON:NFX) aims to raise £210,000 through a conditional placing to advance its NXP002 inhalation treatment for IPF and PPF...

Poolbeg Pharma raises £4.7m through Placing and Subscription

Poolbeg Pharma has successfully raised £4.715 million to fund innovative clinical trials, including POLB 001 and an oral GLP-1 programme, addressing critical medical needs...

AstraZeneca Plc acquires EsoBiotec in $1bn cell therapy deal

AstraZeneca has successfully acquired EsoBiotec, enhancing its cancer therapy capabilities with innovative in vivo cell therapies that promise faster treatment access...

Poolbeg Pharma launches £4.1m fundraising

Poolbeg Pharma plc (LON:POLB) announces a conditional fundraising aimed at raising £4.1 million to drive innovative pharmaceutical developments and address unmet medical needs...

Cizzle Biotechnology raises £150k to support cancer test rollout

Cizzle Biotechnology Holdings Plc has raised £150,000 to advance its CIZ1B early cancer test, enhancing access to innovative diagnostics in the UK and Europe...

Poolbeg Pharma advances in POLB 001 and GLP-1 trials

Poolbeg Pharma Plc has released its audited results for 2024, highlighting significant advancements in cancer immunotherapy, including the promising POLB 001 therapy...

Poolbeg Pharma targets severe flu and cytokine storms

Poolbeg Pharma's POLB 001 is an innovative, orally-administered treatment aiming to combat severe influenza and cytokine release syndrome, revolutionising immunotherapy...

GSK Plc receives Japan approval for Blenrep combinations in multiple myeloma

GSK's Blenrep combinations gain approval in Japan for relapsed multiple myeloma, offering promising treatment options backed by successful clinical trial results...

Nuformix to present NXP002 data at ATS 2025

Nuformix plc will showcase groundbreaking results on NXP002 at the American Thoracic Society Congress in San Francisco, addressing fibrosis and oncology challenges...

One Health Group unlocks new potential in spinal treatment

Experience relief from back pain with One Health Group, a leader in spinal care. Their expert team offers personalised, advanced treatments for improved mobility and quality of life...

Aptamer secures repeat contracts and new licensing deals

Aptamer Group plc announces promising new data on its Optimer therapeutic delivery platform for liver fibrosis, showcasing broad therapeutic potential across various diseases...
Search

Funds

Health

FTSE 100

Funds